Introduction

Myelofibrosis (MF) is a serious, bone marrow disease characterized by spleen enlargement, including large, rigid, pockets, pain, weight, and abdominal pain. The Myelofibrosis Symptom Assessment Form (MFSAF) is a validated questionnaire that measures the burden of MF-related symptoms in patients at rest and at work. In a phase III trial evaluating ruxolitinib in patients with MF-

Methods

The modified MFSAF was used to rate the following MF symptoms on a 0–100 scale (0 = not improved and 100 = very much improved):

1) Night sweats
2) Pruritus, weight loss, and abdominal pain
3) Abdominal pain
4) Pain under the ribs on left side
5) Feeling of fullness (early satiety)
6) Inactivity

The Myelofibrosis Symptom Assessment Form (MFSAF) was designed to evaluate the response of MF patients to treatment [1]. The modified MFSAF v2.0 was used to rate the following MF symptoms on a 0–100 scale (0 = not improved and 100 = very much improved):

1) Night sweats
2) Pruritus, weight loss, and abdominal pain
3) Abdominal pain
4) Pain under the ribs on left side
5) Feeling of fullness (early satiety)
6) Inactivity

Table 1. Spleen Reduction and Improvement in Abdominal Symptoms With Ruxolitinib Treatment

<table>
<thead>
<tr>
<th>Symptom</th>
<th>Placebo (n = 103)</th>
<th>Ruxolitinib (n = 106)</th>
</tr>
</thead>
<tbody>
<tr>
<td>% Reduction of Abdominal Total Symptom Score at Week 24</td>
<td>17.5 ± 19.7</td>
<td>50.4 ± 25.3</td>
</tr>
</tbody>
</table>

Conclusions

Results Using the Modified Myelofibrosis Symptom Assessment Form (MFSAF v2.0) in COMFORT-I: a Randomized, Double-Blind, Phase III Trial of JAK1/2 Inhibitor Ruxolitinib vs. Placebo in Myelofibrosis

R.A. Mesa,1, J.R. Gotlib,2 V. Gupta,2 J.F. DelPersio,2 J. Catalano,2 M. Deininger,2 A. Shields,2 C.B. Miller,3 R.T. Silver,4 M. Talpaz,4 E.F. Winton,4 J.H. Harvey,4 T. Hare,5 S. Eriksson-Viitanen,5 I. Koumenis,5 W. Sun,5 V. Sandor,5 R. Levy,5 H. Kantarjian,5 and S. Verstovsek5 on behalf of all COMFORT-I Investigators.

The COMFORT-I clinical trial was sponsored by Incyte Corporation.

References

